AU2001271824A1 - Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes - Google Patents

Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Info

Publication number
AU2001271824A1
AU2001271824A1 AU2001271824A AU7182401A AU2001271824A1 AU 2001271824 A1 AU2001271824 A1 AU 2001271824A1 AU 2001271824 A AU2001271824 A AU 2001271824A AU 7182401 A AU7182401 A AU 7182401A AU 2001271824 A1 AU2001271824 A1 AU 2001271824A1
Authority
AU
Australia
Prior art keywords
glutathione
prevention
phase
treatment
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271824A
Inventor
Tony Ho
Yun Li
Yueshen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School of Medicine of Johns Hopkins University filed Critical School of Medicine of Johns Hopkins University
Publication of AU2001271824A1 publication Critical patent/AU2001271824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001271824A 2000-07-05 2001-07-05 Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes Abandoned AU2001271824A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21581200P 2000-07-05 2000-07-05
US60/215,812 2000-07-05
PCT/US2001/021225 WO2002002190A2 (en) 2000-07-05 2001-07-05 Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Publications (1)

Publication Number Publication Date
AU2001271824A1 true AU2001271824A1 (en) 2002-01-14

Family

ID=22804500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271824A Abandoned AU2001271824A1 (en) 2000-07-05 2001-07-05 Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Country Status (3)

Country Link
US (1) US6812248B2 (en)
AU (1) AU2001271824A1 (en)
WO (1) WO2002002190A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (en) 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10000577A1 (en) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity
US20020173511A1 (en) * 2000-11-08 2002-11-21 Wurtman Richard J. Serotonergic compositions and methods for treatment of mild cognitive impairment
WO2002087593A1 (en) * 2001-04-25 2002-11-07 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
JP4684553B2 (en) * 2001-09-27 2011-05-18 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア Regulation of physiological processes and drugs useful for this
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
ATE380027T1 (en) 2003-09-09 2007-12-15 Fumapharm Ag USE OF FUMARIC ACID DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND ASTHMA
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
SI1696958T1 (en) * 2003-12-22 2007-08-31 Alcon Inc Agents for treatment of glaucomatous retinopathy and optic neuropathy
WO2005063249A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
PL1577320T3 (en) 2004-03-19 2012-12-31 Pasteur Institut Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
JP2008503479A (en) * 2004-06-16 2008-02-07 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Methods and compositions for modulating Bax-mediated apoptosis
EP1762234A4 (en) * 2004-06-28 2010-05-05 Kao Corp Ampk activator
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
EP2965751A1 (en) 2004-10-08 2016-01-13 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20060116423A1 (en) * 2004-10-18 2006-06-01 Dash Pramod K Methods and compositions for treatment of central nervous system injury with isothiocyanates
US20060174356A1 (en) * 2004-11-09 2006-08-03 Pallanck Leo J Methods and compositions for screening for modulators of neuronal cell death in Parkinson's disease
US7402726B2 (en) 2004-11-09 2008-07-22 The University Of Washington Methods and compositions for screening for modulators of Parkinson's disease
JP2008527002A (en) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US7744937B2 (en) * 2005-08-09 2010-06-29 Kraft Foods Global Brands Llc Chemoprotectants from crucifer seeds and sprouts
EP2086318A4 (en) * 2006-10-10 2009-12-23 Burnham Inst Medical Research Neuroprotective compositions and methods
LT3354267T (en) * 2007-01-23 2019-09-25 Pharmagra Labs, Inc. Stabilized sulforaphane
EP4137819A1 (en) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions and uses for treating multiple sclerosis
ES2599227T3 (en) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotection in demyelinating diseases
US20080311192A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Enteric-Coated Glucosinolates And Beta-Thioglucosidases
US20080311276A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Production of Glucosinolates from Agricultural By-Products & Waste
CA2699813A1 (en) * 2007-09-11 2009-03-19 Joslin Diabetes Center, Inc. Phase ii detoxification and antioxidant activity
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
KR101192699B1 (en) * 2008-11-19 2012-10-19 국립암센터 A pharmaceutical composition for preventing or treating transglutaminase-related disease comprising oltipraz, and a method for preventing or treating transglutaminase-related disease by using thereof
HUE030169T2 (en) 2009-01-09 2017-05-29 Forward Pharma As Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
JP2012525385A (en) * 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of neurodegeneration and neuroinflammation
GB201101793D0 (en) * 2011-02-02 2011-03-16 Univ Edinburgh Weight related disorders
CN103458921B (en) 2011-02-22 2016-05-11 考迪尔种子公司 Spray-dired myrosin and for the production of the purposes of isothiocyanates
EP2709612A4 (en) * 2011-05-19 2015-07-01 Glax L L C Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
ITMI20121774A1 (en) * 2012-10-19 2014-04-20 Placido Bramanti USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM
JP6944690B2 (en) * 2017-02-21 2021-10-06 株式会社アミンファーマ研究所 Glutathione-S-transferase (GST) expression enhancer
US20210052589A1 (en) * 2018-03-07 2021-02-25 Amabiotics Compounds for treating alzheimer's disease
WO2020097320A1 (en) * 2018-11-08 2020-05-14 Neurolign Usa, Llc Rehabilitation of subjects with pharmacologically induced neuroplasticity
EP4061387A1 (en) * 2019-11-18 2022-09-28 Société des Produits Nestlé S.A. Compositions and methods for glutathione enhancement for use in brain health
WO2022047212A1 (en) * 2020-08-27 2022-03-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating neurodegenerative disorders
US11813313B2 (en) 2021-02-25 2023-11-14 Gateway Institute for Brain Research, LLC Method of treating Parkinson's disease with intranasal delivery of insulin and glutathione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
US5780489A (en) 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6369106B1 (en) 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds

Also Published As

Publication number Publication date
WO2002002190A2 (en) 2002-01-10
US6812248B2 (en) 2004-11-02
WO2002002190A3 (en) 2003-08-28
US20020091087A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
AU2001271824A1 (en) Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002240453A1 (en) Wastewater treatment system and method of control
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2001286983A1 (en) Method of treatment
AUPQ515000A0 (en) Treatment of uv induced immunosuppression
AU2002231206A1 (en) Treatment of depression
AU4215499A (en) Treatment of neurodegenerative diseases
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU1261601A (en) Treatment of C. difficile toxin B associated conditions
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2001262177A1 (en) Method of treatment
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU1405001A (en) Treatment of diseases
AU2003264954A1 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease
AU3735900A (en) Methods of treatment and prevention of restenosis
AU2001281465A1 (en) Treatment of rosacea
AU2001253560A1 (en) Methods of treatment
AU2001274080A1 (en) Regulation of human transketolase-like enzyme
AU2002250890A1 (en) Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
AU2001277429A1 (en) Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs